L3VLUP
ProSign in

ICUI · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ICUIVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ICUI
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterICUIVRTX
Q3 202012 holders, $1.1bn31 holders, $21.9bn
Q4 202010 holders, $1.2bn30 holders, $18.4bn
Q1 20219 holders, $1.2bn31 holders, $15.4bn
Q2 20219 holders, $1.1bn30 holders, $12.7bn
Q3 202111 holders, $1.3bn35 holders, $10.1bn
Q4 202111 holders, $1.7bn28 holders, $12.4bn
Q1 20227 holders, $1.6bn23 holders, $16.1bn
Q2 20229 holders, $1.2bn25 holders, $18.1bn
Q3 20227 holders, $802m22 holders, $18.4bn
Q4 20227 holders, $872m28 holders, $18.4bn
Q1 20236 holders, $883m26 holders, $21.4bn
Q2 20236 holders, $919m27 holders, $24.7bn
Q3 20235 holders, $550m33 holders, $24.3bn
Q4 20239 holders, $516m32 holders, $28.6bn
Q1 202410 holders, $569m31 holders, $29.8bn
Q2 202410 holders, $627m29 holders, $33.4bn
Q3 202411 holders, $895m27 holders, $33.5bn
Q4 202411 holders, $670m26 holders, $28.5bn
Q1 202510 holders, $490m21 holders, $35.4bn
Q2 20256 holders, $495m21 holders, $32.3bn
Q3 20255 holders, $527m22 holders, $25.9bn
Q4 20256 holders, $533m26 holders, $31.8bn
Q1 20264 holders, $428m25 holders, $31.8bn
Q2 20264 holders, $502m26 holders, $34.6bn
ICUI

Icu Med Inc

Holders
11
Reported value
$895m
Buyers
5
Sellers
6

Breadth -1 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ICUI (7)

ExodusPoint Capital Management LP, Farallon Capital Management LLC, First Eagle Investment Management LLC, GAMCO Investors Inc, Millennium Management LLC, PDT Partners LLC, Point72 Asset Management LP

Only VRTX (23)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →